Shots:

• Dewpoint to receive up to $305M as up front and milestone along with royalties on sales of any approved product emerges under the collaboration
• The collaboration leverages Dewpoint’s biomolecular condensate platform to develop an HIV drug candidate with a unique mechanism- providing the potential to cure rather than suppressing the infection
• Biomolecular condensates are droplet-like structures that form dynamically within cells when diverse communities of proteins- RNAs- and other biomolecules come together through a process called phase separation

Click here to read full press release/ article 

Ref: Dewpoint | Image: Merck